An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
about
Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank.Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey.Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.Thoughts on health economics in rheumatoid arthritisHealth economic issues in rheumatoid arthritis.Can we derive an 'exchange rate' between descriptive and preference-based outcome measures for stroke? Results from the transfer to utility (TTU) techniqueOutcome measures in rheumatologic clinical trials and systemic sclerosis.A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis.Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis.Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases.How to select the right cost-effectiveness model? : A systematic review and stepwise approach for selecting a transferable health economic evaluation model for rheumatoid arthritis.Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis.A population-based study of health-care resource use among infliximab users.Anti-inflammatory and anti-arthritic activities of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (β-lapachone).Lysyl oxidase is involved in synovial hyperplasia and angiogenesis in rats with collagen‑induced arthritis.Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.Trends in the first decade of 21st century healthcare utilisation in a rheumatoid arthritis cohort compared with the general population.A novel histone deacetylase 6-selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody-induced arthritis mouse model.Cost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
P2860
Q33451953-6F7FAF63-5D1C-46AC-8B99-3E3CC14CD129Q34099501-B0098FE5-3427-4886-9523-966938D54498Q35001257-E41C999F-6801-4989-91E3-DB18EDB1EF95Q35579517-F8E59090-E1F8-4D42-9F9E-F872198B04B0Q36052572-D51FF236-A621-478C-AB48-836EB7ED9B8FQ36171777-F68AA4D4-D837-4AC6-AD32-588C23AE2EF2Q36753625-6940821E-F780-4775-907B-BF9A87A8C834Q37187640-8D58996D-F98D-4DB9-B0D0-5C4552464851Q37265816-4F2C64CA-2502-41A8-9E9B-49D5651B30EEQ37609399-57FCB561-BA30-4528-8331-18BE18AA7C1CQ37848117-49C3A39A-5EDE-48C0-A2F5-95005050AFC6Q38008692-3E09583E-DAFF-4B19-83D2-85D661081075Q38185992-7313BDDE-A0E0-4671-ACB6-CF14DDC5CCF8Q38650525-9405AC96-E71D-4D57-91D4-D53C9633510EQ43107861-A975EF78-E7C9-4A30-833A-6401F1CDFAD6Q45248130-9D5965BD-76DD-4E20-A35A-AE8C08C0ACC4Q50122722-C3E67A97-16A1-4A85-A1F0-82510AF374DFQ51129676-6D76F52B-A471-4E42-AE42-CBE0D0D497FBQ51200468-456999FA-1CDE-4E9C-A7DB-BEC85E364C51Q53662447-B82158A9-B417-4EC3-804F-8F1F56C28A97Q57658712-B8AAB560-ECF6-4C72-B3F0-7D9F05756406
P2860
An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
An overview of economic evalua ...... osis factor-alpha antagonists.
@ast
An overview of economic evalua ...... osis factor-alpha antagonists.
@en
type
label
An overview of economic evalua ...... osis factor-alpha antagonists.
@ast
An overview of economic evalua ...... osis factor-alpha antagonists.
@en
prefLabel
An overview of economic evalua ...... osis factor-alpha antagonists.
@ast
An overview of economic evalua ...... osis factor-alpha antagonists.
@en
P2093
P50
P1433
P1476
An overview of economic evalua ...... osis factor-alpha antagonists.
@en
P2093
Aslam H Anis
Carlo A Marra
John M Esdaile
Kamran Shojania
Roberta Ara
P304
P356
10.2165/00003495-200565040-00004
P577
2005-01-01T00:00:00Z
P6179
1017825554